Literature DB >> 3262464

Selective cytotoxicity of an oxygen-radical-generating enzyme conjugated to a monoclonal antibody.

M G Battelli1, A Abbondanza, P L Tazzari, A Dinota, S Rizzi, G Grassi, M Gobbi, F Stirpe.   

Abstract

The monoclonal antibody 8A, which recognizes a human plasma cell-associated antigen, was covalently linked to xanthine oxidase in a conjugate maintaining both immunological and enzymatic properties. A significant degree of target cell lysis was obtained at an enzyme concentration that was ineffective on non-target cells and on myeloid staminal cells (CFU-GM). The cytotoxic activity was abolished by an excess of antibody, by allopurinol and by superoxide dismutase and catalase. A possible use of the conjugate for bone marrow purging in multiple myeloma patients is suggested.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262464      PMCID: PMC1541466     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Ribosome-inactivating proteins up to date.

Authors:  F Stirpe; L Barbieri
Journal:  FEBS Lett       Date:  1986-01-20       Impact factor: 4.124

Review 2.  Xanthine oxidase: biochemistry, distribution and physiology.

Authors:  D A Parks; D N Granger
Journal:  Acta Physiol Scand Suppl       Date:  1986

Review 3.  Immunotoxins.

Authors:  I Pastan; M C Willingham; D J FitzGerald
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

4.  The kinetics of antibody binding to membrane antigens in solution and at the cell surface.

Authors:  D W Mason; A F Williams
Journal:  Biochem J       Date:  1980-04-01       Impact factor: 3.857

5.  Antibody-directed urokinase: a specific fibrinolytic agent.

Authors:  C Bode; G R Matsueda; K Y Hui; E Haber
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

6.  Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies.

Authors:  P L Tazzari; M Gobbi; A Dinota; A Bontadini; G Grassi; C Cerato; M Cavo; S Pileri; F Caligaris-Cappio; S Tura
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

Review 7.  Prospects for immunotoxin therapy in cancer.

Authors:  A E Frankel; L L Houston; B F Issell; G Fathman
Journal:  Annu Rev Med       Date:  1986       Impact factor: 13.739

8.  Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues.

Authors:  T D Engerson; T G McKelvey; D B Rhyne; E B Boggio; S J Snyder; H P Jones
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent.

Authors:  J Carlsson; H Drevin; R Axén
Journal:  Biochem J       Date:  1978-09-01       Impact factor: 3.857

10.  Bactericidal activity of a superoxide anion-generating system. A model for the polymorphonuclear leukocyte.

Authors:  H Rosen; S J Klebanoff
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

View more
  4 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  T lymphocyte killing by a xanthine-oxidase-containing immunotoxin.

Authors:  M G Battelli; A Abbondanza; P L Tazzari; A Bolognesi; R M Lemoli; F Stirpe
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research.

Authors:  Andrea Bolognesi; Massimo Bortolotti; Maria Giulia Battelli; Letizia Polito
Journal:  Molecules       Date:  2017-01-27       Impact factor: 4.411

Review 4.  Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects.

Authors:  Maria Giulia Battelli; Letizia Polito; Massimo Bortolotti; Andrea Bolognesi
Journal:  Oxid Med Cell Longev       Date:  2015-12-28       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.